News
Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.
Recommendations for Substitution Therapy with Immunoglobulins in Hemato-oncological Patients with Secondary Immunodeficiency – Expert Consensus According to the DELPHI Methodology
Substitution therapy with immunoglobulins is used not only for patients with primary immunodeficiencies....
How Does Emicizumab Work in Obese Adults with Hemophilia A?
What is the annual bleeding rate and minimum concentration of emicizumab in obese adults with…
Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis
Data from randomized clinical trials have shown that romiplostim is an effective medication for…
How TPO-RA Drugs Fared in Meta-Analyses of Safety and Efficacy in ITP Patients
Meta-analyses regarding the use of thrombopoietin receptor agonists (TPO-RA) evaluated their…
Expanded Hemodialysis and Its Impact on Reducing Hospitalization Rates and Medication Usage
The number of patients with end-stage kidney disease is increasing. New approaches and…
Efficacy of Brigatinib in Patients with Metastatic NSCLC − Real-World Clinical Data
The journal Lung Cancer published the results of a retrospective analysis of the efficacy of…
Monocyte Distribution Width Indicates Sepsis Regardless of Sepsis Etiology
Patients in intensive care units represent a high-risk population for the development of sepsis,…
News in Laboratory Diagnostics of Early Sepsis − First Czech Experiences
Sepsis represents one of the most frequent causes of morbidity and mortality in critically ill…
Final Analysis of the STASEY Study: How Did Emicizumab Perform in Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?
The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021…